Chemocentryx, Inc.

UEI
EVYLGAKQEUL8
CAGE
1KMV4
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Founded
1997
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 -$21,632
FY2023 $128,986

Contract awards

Award Agency Obligated Awarded
Tavneos (avacopan) boise VAMC 36C26023F0102 Veterans Integrated Service Network 20 (VHA) $107,354
Definitive Contract N6600101C8009 Naval Information Warfare Systems Command (Navy) $1,847,355

Grant awards

Award Agency Obligated Awarded
Phase 2 study of avacopan for treatment of C3G, IND 132321, orphan designation 16-5590 R01FD006342 FDA Office of Acquisition and Grant Services $1,000,000
Phase 2 studies of CCX168 for treatment of anca-vasculitis IND120784, OD14-4320 R01FD005414 Food and Drug Administration $500,000
Chemokine adjuvants for biothreat pathogen vaccines U19AI056690 National Institutes of Health $3,124,002

Similar vendors

Vendor Location Primary NAICS
Sobi, Inc. UEI S2TUAPDB2971 Waltham, MA 325412 Pharmaceutical Preparation Manufacturing
Rigel Pharmaceuticals Inc. UEI X7MHPBCMHFM3 South San Francisco, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Alexion Pharmaceuticals Inc. UEI DKCXLGANZAN3 Boston, MA 325412 Pharmaceutical Preparation Manufacturing
Mirum Pharmaceuticals, Inc. UEI U8E2HFXRE9X3 San Mateo, CA 325412 Pharmaceutical Preparation Manufacturing
U.s. Division UEI XEEKF6DJLC34 Rockville, MD 424210 Drugs and Druggists' Sundries Merchant Wholesalers

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Chemocentryx, Inc., doing business as Chemocentryx, is a biopharmaceutical company that develops and provides specialty medications, including the drug TAVNEOS, to treat rare autoimmune diseases. According to its website, Chemocentryx focuses on discovering, developing, and commercializing therapies targeting chemokine receptors and related chemoattractants.

Through past prime federal contract awards, Chemocentryx has provided the specialty medication TAVNEOS to Department of Veterans Affairs (VA) medical facilities. This includes a $128,986 firm fixed price delivery order from VA Veterans Integrated Service Network 20 to provide TAVNEOS to the Boise VA Medical Center by December 2023. Chemocentryx also holds a $12 million single-award blanket purchase agreement with the VA National Acquisition Center through August 2023 to supply TAVNEOS to VA locations nationwide. Additionally, Chemocentryx was awarded a $225,000 Federal Supply Schedule contract by the VA Veterans Health Administration to provide drugs, pharmaceuticals, and hematology related products, including TAVNEOS, through August 2027.

Through a past federal grant, Chemocentryx received $1 million from the Food and Drug Administration to conduct a Phase 2 clinical trial studying the use of TAVNEOS to treat C3 glomerulopathy through January 2022. This grant award utilized an orphan drug designation to fund continued research and development of TAVNEOS.

Chemocentryx holds several federal Indefinite Delivery/Indefinite Quantity contract vehicles to provide TAVNEOS through VA channels. This includes the $12 million single-award blanket purchase agreement with the VA National Acquisition Center through August 2023. Chemocentryx also holds a $515,865 single-award blanket purchase agreement with the VA National Acquisition Center that runs through October 2022. Additionally, the $225,000 Federal Supply Schedule contract with the VA Veterans Health Administration enables TAVNEOS delivery through task orders over its period of performance through August 2027.

Quick answers

Is Chemocentryx, Inc. registered in SAM.gov?

Chemocentryx, Inc.'s SAM.gov registration expired on June 21, 2023.

How much has Chemocentryx, Inc. received in federal contracts?

Federal contracts obligated $107,354 to Chemocentryx, Inc. in fiscal years 2023 through 2027.

What is Chemocentryx, Inc.'s most recent federal award?

Chemocentryx, Inc.'s most recent federal contract award is Tavneos (avacopan) boise VAMC (36C26023F0102), from Veterans Integrated Service Network 20 (VHA), on December 16, 2022.

On GovTribe

See Chemocentryx, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login